CDK inhibitor Palbociclib targets STING to alleviate autoinflammation

  • Gao J
  • Zheng M
  • Wu X
  • et al.
33Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aberrant activation of stimulator of interferon genes (STING) is tightly associated with multiple types of disease, including cancer, infection, and autoimmune diseases. However, the development of STING modulators for the therapy of STING-related diseases is still an unmet clinical need. We employed a high-throughput screening approach based on the interaction of small-molecule chemical compounds with recombinant STING protein to identify functional STING modulators. Intriguingly, the cyclin-dependent protein kinase (CDK) inhibitor Palbociclib was found to directly bind STING and inhibit its activation in both mouse and human cells. Mecha-nistically, Palbociclib targets Y167 of STING to block its dimeriza-tion, its binding with cyclic dinucleotides, and its trafficking. Importantly, Palbociclib alleviates autoimmune disease features induced by dextran sulphate sodium or genetic ablation of three prime repair exonuclease 1 (Trex1) in mice in a STING-dependent manner. Our work identifies Palbociclib as a novel pharmacological inhibitor of STING that abrogates its homodimerization and provides a basis for the fast repurposing of this Food and Drug Administration-approved drug for the therapy of autoinflamma-tory diseases.

Cite

CITATION STYLE

APA

Gao, J., Zheng, M., Wu, X., Zhang, H., Su, H., Dang, Y., … Liu, H. (2022). CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. EMBO Reports, 23(6). https://doi.org/10.15252/embr.202153932

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free